STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
Phase 3positiveVaxcyte pneumococcal vaccinePositive
AI Analysis
Summary
Vaxcyte's pneumococcal vaccine achieved primary endpoints in Phase 3 clinical trial, positioning the company to compete with established players Pfizer and Merck in the pneumococcal vaccine market.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
hit primary endpoints
Importance:7/10
Sentiment:
0.70
vaccinepneumococcalPhase 3clinical trialcompetitive landscape
Read the original article
Published by STAT News on October 5, 2026 1:10 PM